Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942081 | 0.88 | TSHR (0.43) | L3MBTL1MAPTMAPK1TDP1S1PR4 | |
| SCHEMBL16491623 | 0.83 | HTT (0.59) | L3MBTL1MAPTMAPK1TDP1S1PR4 | |
| SCHEMBL718946 | 0.80 | MAPT (0.43) | L3MBTL1MAPTMAPK1TDP1STAT3 | |
| SCHEMBL16415760 | 0.80 | MEN1 (0.52) | L3MBTL1MAPTMAPK1TDP1STAT3 | |
| SCHEMBL11067263 | 0.80 | LTA4H (0.58) | L3MBTL1MAPTMAPK1TDP1STAT3 | |
| SCHEMBL3947830 | 0.78 | SMN1; SMN2 (0.58) | L3MBTL1MAPTMAPK1TDP1STAT3 | |
| SCHEMBL24975372 | 0.78 | HTR2C (0.41) | L3MBTL1MAPTMAPK1TDP1STAT3 | |
| SCHEMBL12226851 | 0.78 | L3MBTL1 (0.49) | L3MBTL1MAPTMAPK1TDP1STAT3 | |
| SCHEMBL4502335 | 0.78 | MAPT (0.49) | L3MBTL1MAPTMAPK1TDP1STAT3 | |
| SCHEMBL3869852 | 0.78 | L3MBTL1 (0.49) | L3MBTL1MAPTMAPK1TDP1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667256-A | Compounds for treating diseases and methods of treating diseases | 艾特里提治疗有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | L3MBTL1 2678/4885MAPT 6/4885MAPK1 2046/4885 |
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | L3MBTL1 3496/4885MAPT 3204/4885MAPK1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.